日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. LYPD3 (Lupartumab Biosimilar) Recombinant Monoclonal Antibody

LYPD3 (Lupartumab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA013263MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    LYPD3（Lupartumab Biosimilar Antibody）重組單克隆抗體是一種靶向LYPD3蛋白，其別名為2310061G07Rik抗體、C4.4A抗體、GPI錨定轉(zhuǎn)移相關(guān)蛋白C4.4A同源物抗體、Ly6/PLAUR結(jié)構(gòu)域包含蛋白3抗體等，也可簡稱為Lypd3抗體或Lupartumab。該抗體以重組人LYPD3蛋白制備，具有明確的靶向性和生物活性。 Lupartumab Biosimilar Antibody作為靶向LYPD3抗體，Lupartumab類似物，其靶點LYPD3（又稱C4.4A）屬于GPI錨定蛋白家族，在多種腫瘤中高表達，與腫瘤侵襲、轉(zhuǎn)移及預(yù)后密切相關(guān)。目前，Lupartumab的臨床應(yīng)用研究主要集中在其作為抗腫瘤治療藥物的潛力，探索其在乳腺癌、肺癌、胰腺癌等實體瘤中的治療價值，包括單藥治療或與化療、免疫治療聯(lián)合應(yīng)用的療效及安全性評估，有望為腫瘤精準治療提供新策略。 LYPD3抗體展現(xiàn)出廣泛的種屬反應(yīng)性，可與人、大鼠、小鼠及食蟹猴（Macaca fascicularis）的LYPD3蛋白發(fā)生特異性結(jié)合。這一特性使其適用于跨物種的基礎(chǔ)研究，研究者可利用該抗體在細胞實驗（如、）和動物模型（如腫瘤異種移植模型）中，深入探究LYPD3蛋白的生理功能、表達調(diào)控機制及其在疾病發(fā)生發(fā)展中的作用，為揭示相關(guān)疾病的分子機制和開發(fā)新型治療手段提供重要工具。
  • Uniprot No.：
  • 基因名：
  • 別名：
    2310061G07Rik antibody; C4.4A antibody; GPI-anchored metastasis-associated protein C4.4A homolog antibody; GPI-anchored metastasis-associated protein homolog antibody; Ly6/PLAUR domain-containing protein 3 antibody; Lypd3 antibody; LYPD3_HUMAN antibody; Matrigel-induced gene C4 protein antibody; MIG-C4 antibody; SHINC3 antibody; Lupartumab
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human LYPD3 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    In stock
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點詳情

  • 功能：
    Supports cell migration. May be involved in urothelial cell-matrix interactions. May be involved in tumor progression.
  • 基因功能參考文獻：
    1. While in the healthy liver hepatocytes are C4.4A negative, data show that C4.4A is strongly expressed in hepatocellular carcinoma (HCC) with upregulation at the invasive front and in lung metastasis, indicating that C4.4A apparently contributes to HCC progression. PMID: 29048672
    2. Our results are consistent with previous data in mouse embryogenesis and wound healing. Based on these findings, we conclude that this human TES model provides an excellent surrogate for studies of C4.4A and Haldisin expressions in human stratified epithelia. PMID: 29075641
    3. Expression and crystallographic studies of the D1D2 domains of C4.4A have been reported. PMID: 28777093
    4. LYPD3 has a role in the maintenance of colorectal cancer stem-like cells. PMID: 28238780
    5. Highly expressed C4.4A protein in HER2-positive human breast cancers indicate a good prognosis. PMID: 23918676
    6. overexpression of C4.4A correlates with metastatic potential of gastric cancer and C4.4A could be a novel independent prognostic marker for predicting outcome. PMID: 24935570
    7. expression of the Ly6/uPAR-domain proteins C4.4A and Haldisin in non-invasive and invasive skin lesions PMID: 25414274
    8. Tenascin-C expression was significantly associated with C4.4A expression in clinical esophageal squamous carcinoma samples suggesting that there may be a functional role for the C4.4A to induceTenascin-C in vivo. PMID: 23708783
    9. findings suggest that a tight association between C4.4A and tumor budding may, in part, be due to C4.4A promoting epithelial-mesenchymal transition at the invasive front of colorectal cancer PMID: 22404718
    10. the first explanation for the C4.4A contribution to wound healing and metastasis. PMID: 22431918
    11. data indicate that expression of the C4.4A protein at the invasive front acts as a novel prognostic marker in colorectal cancer, possibly through invasion-related mechanisms PMID: 20825414
    12. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan PMID: 12592373
    13. High tumour cell C4.4A expression is associated with shorter survival for non-small cell lung cancer patients. PMID: 17706320
    14. Overexpression of C4.4A is associated with invasion and metastasis of esophageal squamous cell carcinoma PMID: 17849475
    15. we consider C4.4A as a candidate diagnostic marker in colorectal cancer, which possibly can be detected in body fluids PMID: 17912244
    16. cleavage of C4.4A by ADAM10 and ADAM17 contributes to tumor progression PMID: 18979631

    顯示更多

    收起更多

  • 亞細胞定位：
    Cell membrane; Lipid-anchor, GPI-anchor.
  • 組織特異性：
    Expressed in placenta, skin and urothelium. Found in suprabasal keratinocytes of chronic wounds. Weak expression is found in esophagus and peripheral blood mononuclear cells. Found in the majority of primary and metastatic transitional cell carcinomas (TC
  • 數(shù)據(jù)庫鏈接：

    HGNC: 24880

    OMIM: 609484

    KEGG: hsa:27076

    STRING: 9606.ENSP00000244333

    UniGene: Hs.631594



×
生命科學(xué)計算平臺